# A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

> **NCT05669014** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 12 (actual)

## Conditions studied

- Idiopathic Inflammatory Myositis

## Interventions

- **DRUG:** Daxdilimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05669014
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-04
- **Primary completion:** 2025-07-02
- **Final completion:** 2025-07-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669014, "A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05669014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*